Effectiveness and Safety of ANTI SARS-CoV-2 Vaccination in Transplant Patients Treated with Immunosuppressants: A Real-World Pilot Study with a 1-Year Follow-Up

SARS-CoV-2 is a betacoronavirus, which induced a severe pandemic infectious disease around the world. Even if several drugs have been suggested for its treatment, to date, the only strategy to reduce the severity of disease is represented by the use of vaccine. However, the lack of pre-marketing evidence in frail patients suggests the necessity of the real-world study of a vaccine benefit–risk profile. In this study, we evaluated the efficacy and the safety of SARS-CoV-2 vaccination in a cohort of 33 patients treated with an immunosuppressant after solid organ transplant. Both CLIA and LS/MS analysis were used to evaluate the levels of immunoglobulin (Ig)G anti SARS-CoV-2 and the therapeutic drug monitoring of immunosuppressant drugs. We documented that SARS-CoV-2 vaccination induced a dose- and gender-related serological response. In particular, in 63.6% of the enrolled patients, we documented a significant serological response at T2, and after a time related decrease, the booster dose induced a serological response in 72.7% of enrolled patients. In conclusion, the vaccine anti SARS-CoV-2 is immunogenic in patients under immunosuppression, and is not related to the development of ADRs. We also suggest that the booster dose could be used to increase the efficacy of the vaccination, particularly in women.

[1]  K. Macháleková,et al.  Acute kidney rejection after anti-SARS-CoV-2 virus-vectored vaccine—case report , 2022, NPJ vaccines.

[2]  P. Kelleher,et al.  Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression , 2021, Annals of the Rheumatic Diseases.

[3]  P. Mosaddeghi,et al.  Administration of COVID-19 vaccines in immunocompromised patients , 2021, International Immunopharmacology.

[4]  J. Achard,et al.  Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients , 2021, Journal of the American Society of Nephrology : JASN.

[5]  A. Sattler,et al.  Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. , 2021, Science immunology.

[6]  T. Kalina,et al.  Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients , 2021, The Journal of Heart and Lung Transplantation.

[7]  D. Segev,et al.  Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.

[8]  P. Maingon,et al.  Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients , 2021, Annals of Oncology.

[9]  G. Rahav,et al.  BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response , 2021, The Journal of Heart and Lung Transplantation.

[10]  B. Rovin,et al.  Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy , 2021, Kidney International.

[11]  D. Segev,et al.  Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[12]  B. Rovin,et al.  Gross Hematuria Following Vaccination for SARS-CoV2 in Two Patients with IgA Nephropathy , 2021, Kidney International.

[13]  M. Ison,et al.  Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Ralf Bartenschlager,et al.  Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.

[15]  C. Libert,et al.  The X chromosome in immune functions: when a chromosome makes the difference , 2010, Nature Reviews Immunology.

[16]  L. Gallelli,et al.  Venlafaxine–Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation , 2008, The Annals of pharmacotherapy.